Incretin-based therapies have revolutionized the management of type 2 diabetes and obesity by harnessing the physiological actions of gut-derived hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.